<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="418">
  <stage>Registered</stage>
  <submitdate>6/01/2004</submitdate>
  <approvaldate>6/01/2004</approvaldate>
  <nctid>NCT00075218</nctid>
  <trial_identification>
    <studytitle>A Study To Assess The Safety And Efficacy Of SU11248 In Patients With Gastrointestinal Stromal Tumor(GIST)</studytitle>
    <scientifictitle>A Phase III, Randomized, Double-Blind, Placebo-Controlled Study Of SU011248 In The Treatment Of Patients With Imatinib Mesylate (Gleevec Tm, Glivec)-Resistant Or Intolerant Malignant Gastrointestinal Stromal Tumor</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>A6181004</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Gastrointestinal Stromal Tumor</healthcondition>
    <conditioncode>
      <conditioncode1>Cancer</conditioncode1>
      <conditioncode2>Stomach</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Cancer</conditioncode1>
      <conditioncode2>Bowel - Small bowel (duodenum and ileum)</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Cancer</conditioncode1>
      <conditioncode2>Bowel - Back passage (rectum) or large bowel (colon)</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Treatment: drugs - Placebo
Treatment: drugs - SU011248

Placebo Comparator: B - 

Active Comparator: A - 


Treatment: drugs: Placebo
50 mg taken orally once a day. 6 week treatment cycle (Schedule 4/2) 4 weeks on study drug/2 weeks off study drug.

Treatment: drugs: SU011248
50 mg taken orally once a day. 6 week treatment cycle (Schedule 4/2) 4 weeks on study drug/2 weeks off study drug.

</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Time to Tumor Progression (TTP) as Assessed by Imaging Studies at End of Double-blind Treatment Phase</outcome>
      <timepoint>Day 28 of each 6-week cycle : duration of double-blind treatment phase</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Time to Tumor Progression (TTP) as Assessed in the Double-blind Treatment Phase at End of Study</outcome>
      <timepoint>Day 28 of each 6-week cycle : duration of double-blind treatment phase after Last Subject Last Visit (LSLV)</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Progression Free Survival (PFS)</outcome>
      <timepoint>Day 28 of each cycle : duration of double-blind treatment phase</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Overall Survival Status of Subjects</outcome>
      <timepoint>clinic visit or telephone contact every 2 months for up to 3 years from the last dose of study drug</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Overall Survival</outcome>
      <timepoint>clinic visit or telephone contact every 2 months for up to 3 years from the last dose of study drug</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Overall Survival Based on the Rank Preserving Structural Failure Time Method</outcome>
      <timepoint>clinic visit or telephone contact every 2 months for up to 3 years from the last dose of study drug</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Best Overall Tumor Response During Double-blind Treatment Phase</outcome>
      <timepoint>Day 28 of each cycle : duration of double-blind treatment phase</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Confirmed Objective Response (CR or PR) in Subjects</outcome>
      <timepoint>Day 28 of each cycle : duration of double-blind treatment phase</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Time to Tumor Response (TTR)</outcome>
      <timepoint>Day 28 of each cycle : duration of double-blind treatment phase</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Duration of Performance Status Maintenance</outcome>
      <timepoint>Day 28 of each cycle : duration of double-blind treatment phase</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Time to Pain Progression Using McGill Pain Questionnaire-present Pain Intensity (MPQ-PPI)</outcome>
      <timepoint>Day 1 &amp; 28 of each cycle : duration of double-blind treatment phase</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Subjects With Pain Relief Response Using McGill Pain Questionnaire-present Pain Intensity (MPQ-PPI)</outcome>
      <timepoint>Day 1 &amp; 28 of each cycle : duration of double-blind treatment phase</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Change From Baseline Score in EuroQoL Visual Analog Scale (EQ-VAS)</outcome>
      <timepoint>Day 1 &amp; 28 of each cycle : duration of double-blind treatment phase</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Change From Baseline in EQ-5D Health State Profile Index</outcome>
      <timepoint>Day 1 &amp; 28 of each cycle : duration of double-blind treatment phase</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Key 

          -  Histologically-proven diagnosis of malignant GIST not amenable to surgery, radiation
             or combined modality treatment with curative intent

          -  Failed Gleevec treatment or intolerant to Gleevec therapy

        Key</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage />
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>-  Treatment with any chemotherapy, chemoembolization therapy, immunotherapy, or
             investigational agent since the last dose of Gleevec</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Crossover</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1>The people receiving the treatment/s</masking1>
    <masking2 />
    <masking3 />
    <masking4>The people analysing the results/data</masking4>
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 3</phase>
    <anticipatedstartdate />
    <actualstartdate>1/12/2003</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize />
    <actualsamplesize>361</actualsamplesize>
    <recruitmentstatus>Completed</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate>1/05/2008</actuallastvisitdate>
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>ACT,NSW,QLD,SA,VIC</recruitmentstate>
    <hospital>Pfizer Investigational Site - Garran</hospital>
    <hospital>Pfizer Investigational Site - Camperdown</hospital>
    <hospital>Pfizer Investigational Site - Randwick</hospital>
    <hospital>Pfizer Investigational Site - Auchenflower</hospital>
    <hospital>Pfizer Investigational Site - Ashford</hospital>
    <hospital>Pfizer Investigational Site - Bedford Park</hospital>
    <hospital>Pfizer Investigational Site - East Melbourne</hospital>
    <postcode>2605 - Garran</postcode>
    <postcode>2050 - Camperdown</postcode>
    <postcode>2031 - Randwick</postcode>
    <postcode>4066 - Auchenflower</postcode>
    <postcode>5035 - Ashford</postcode>
    <postcode>5042 - Bedford Park</postcode>
    <postcode>3002 - East Melbourne</postcode>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>California</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>District of Columbia</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Florida</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Illinois</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Massachusetts</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Michigan</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Minnesota</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Missouri</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>New York</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>North Carolina</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Ohio</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Oregon</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Pennsylvania</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Tennessee</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Washington</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Wisconsin</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Belgium</country>
      <state>Leuven</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>Ontario</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>Quebec</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Lyon</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Marseille</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>VILLEJUIF Cedex</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>PN</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Torino</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Bologna</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Genova</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Milano</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Netherlands</country>
      <state>Gr</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Netherlands</country>
      <state>ZH</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Singapore</country>
      <state>Singapore</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Barcelona</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Madrid</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Switzerland</country>
      <state>Lausanne</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Surrey</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Leeds</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>London</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Newcastle-Upon-Tyne</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Pfizer</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
  </sponsorship>
  <ethicsAndSummary>
    <summary>A study to assess the safety and efficacy of SU11248 in patients with gastrointestinal
      stromal tumor (GIST) whose disease has failed imatinib therapy or who were intolerant to
      imatinib treatment.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT00075218</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Pfizer CT.gov Call Center</name>
      <address>Pfizer</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>